Institutions: Norwegian University of Science and Technologyhttps://orcid.org/0000-0002-9044-4742
Senior Research Scientist at SINTEF, Dept. of Biotechnology and Nanomedicine, Research Group Mass Spectrometry
Since 1st of January 2015 I am Professor in synthetic biology at the Norwegian University of Science and Technology (NTNU) institute of biotechnology. Before that I was research director in the non-profit research institution SINTEF. My major research activities are within microbial molecular biology, mainly combining metabolic engineering, synthetic biology and systems biology to develop microbial cell factories, and focusing both on the products and on the raw materials. The research includes
I am a PostDoc in prof. Brautaset's lab at NTNU in Trondheim, Norway. During my Ph studies D, Irla was involved in two ERA projects; SynMet and MetAPP (PAL) and currently in I am active in C1Pro project (Asset housekeeper). I have been working with methylotrophic Bacillus methanolicus since 2012, in that time I have been involved in engineering of that bacterium for production of different value-added products (amino acids and their derivatives, vitamins, and others). Furthermore, I have improved
Here we share resources and best practices to develop a disease map for COVID-19. The project is progressing as a broad community-driven effort. We aim to establish a knowledge repository on virus-host interaction mechanisms specific to the SARS-CoV-2. The COVID-19 Disease Map is an assembly of molecular interaction diagrams established based on literature evidence.
In this project, we integrate COVID19 Disease Maps curated regulatory information in a macrophage logical model.
This allows logical simulations of the effects of acute inflammation caused by the SARS-CoV-2 virus, both in general and in a cell-specific perspective. Moreover, understanding the regulatory network behavior of macrophages following infection opens new ways to test and predict drug and drug combination effects, as a first step towards the development of new treatments.
This is a sandbox where DigiSal members can learn to use the SEEK.
Tutorial document: http://tinyurl.com/seek-ds17
The SEEK is a web interface to a database of research "assets" organised in a hierarchical "ISA structure" (investigation-study-assay) .
These are further organised into projects and programmes.
* Programme = Overarching research theme (The Digital Salmon)
* Project = Research grant (DigiSal, GenoSysFat)
* Investigation = a particular biological process, phenomenon or thing
Salmon farmed on modern feeds contains less of the healthy, long-chain fatty acids (EPA and DHA) than before. Up until the turn of the millennium, farmed salmon were fed fish oil as a replacement for their omega-3 rich natural prey. However, fish oil is now a scarce resource, and more than half of the fat in modern feeds comes from plant oils that are inexpensive, but devoid of long-chain omega-3 fatty acids. How can we increase the omega-3 content of salmon on sustainable feeds?
One option is
Towards the Digital Salmon: From a reactive to a pre-emptive research strategy in aquaculture (DigiSal)
Salmon farming in the future must navigate conflicting and shifting demands of sustainability, shifting feed prices, disease, and product quality. The industry needs to develop a flexible, integrated basis of knowledge for rapid response to new challenges. Project DigiSal will lay the foundations for a Digital Salmon: an ensemble of mathematical descriptions of salmon physiology, combining
Increasing temperature in the European wine producing regions is having a negative impact on this key sector. Climate change results in a lack of balance between technological and phenolic ripening of wine grapes and, as a consequence, alcohol increase in wines. This trend is of great concern for the European wine industry because it has a negative impact on wine quality, becomes a hurdle for international trade, and jeopardizes compatibility of moderate wine consumption with a healthy lifestyle.
Coastal zones and oceans constitute an essential fundament for Norway’s history as well as current economy, providing ecosystem services for fisheries, aquaculture, transport, tourism, and recreation. The petroleum activities in Norwegian waters have been crucial for Norway’s financial growth and in financing the Norwegian welfare state. As the pressure on the oceans continuously increases, both the petroleum industry and the seafood industries have acknowledged that awareness and actions are
A joint NTNU and SINTEF project to establish a knowledge platform on DHA synthesis and lipid accumulation in the native DHA-producing thraustochytrids, and to develop these into high productivity omega-3 fatty acid producing cell factories.
The COLOSYS project aims to develop a deeper understanding of colon cancer networks and convert them into computer models with which it will be better to predict response to treatment. The combination of computational, experimental and clinical testing will provide understanding of drug resistance mechanisms, and allow personalised treatment of colon cancer.
INBioPharm - Integrated Novel Natural Product Discovery and Production Platform for Accelerated Biopharmaceutical Innovation from Microbial Biodiversity project will develop a new, generic technology platform for the more efficient discovery of novel bioactive compounds with improved prospects to become medical products. A unique national collection of marine microorganisms at SINTEF/NTNU will be used as the basis for the development of different new, complementary molecular biology, analytical
Programme: Independent Projects
Public web page: https://digitallifenorway.org/gb/projects/inbiopharm
Organisms: Streptomyces coelicolor
The project “Rational development of anti-cancer combinations” focuses on precision medicine for cancer by pursuing novel insight into cancer disease mechanisms, combinatorial drug treatment in order to enable selection of the best treatment for the individual patient. The aim is to develop and integrate computational, experimental and analytical approaches to predict and validate anti-cancer drug combinations and produce an integrated pipeline for rational screening of synergistic drugs and for
In the project “Crossover Research 2.0 – Well constructed Knowledge Commons” the domain of precision medicine is explored as a key visionary driver for developing the Knowledge Commons and the enabling of Systems Biology approaches to innovate healthcare. In particular, we seek to engage stakeholder concerns in investigating and establishing strategies for DrugLogics to contribute to the Knowledge Commons in an RRI mode.